Clinical Research Directory

Inclusion criteria by study group: 1. Participants with Motor Complete SCI: * 18-65 years old, * Stable medical condition, * At least 1-year post-injury, * Non-progressive SCI, * Motor complete paraplegia: Unable to voluntarily move any joint of the lower limbs, * Inability to walk independently due to SCI, * Presence of active spinally evoked responses over the lumbo-sacral spinal cord using spinal Cord Transcutaneous Stimulation (scTS). 2. Participants with Motor Incomplete SCI: * 18-65 years old, * Stable medical condition, * At least 1-year post-injury, * Non-progressive SCI, * Motor incomplete paraplegia: Able to voluntarily move at least 1 joint of the lower limbs bilaterally, * Inability to walk independently in the community due to SCI, * Presence of active spinally evoked responses over the lumbo-sacral spinal cord using scTS. Exclusion Criteria: * Untreated pressure sores, * Unhealed bone fractures, * Untreated active urinary tract infections, * Peripheral lower limb neuropathies unrelated to SCI, * Seizure disorders, * Cardiopulmonary disease unrelated to SCI, * Untreated anemia, * Ventilator dependency, * Female participants: Pregnant or planning to become pregnant during the time course of study, or nursing, * Healing wounds/surgical sites along the spine, levels T9-L5, * Anti-spasticity implantable pumps, * Untreated clinically significant depression, psychiatric disorders, or ongoing drug abuse, * Colostomy bag, urostomy, * Individuals with abnormal blood panel results related to hepatic function, Individuals with abnormal estimated glomerular filtration rate (eGFR) and increase Creatinine Clearance (CrCl) levels above the normal range, * Individuals unwilling or unable to wean from drug(s) that interact(s) with buspirone, such as: Monoamine oxidase inhibitors (MAOIs) - Selegiline (Emsam), Isocarboxazid (Marplan), Phenelzein (Nardil), and Tranylcypromine (Parnate).